导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.85% | 2184/4773 |
| 近一周 | -1.39% | 2118/5465 |
| 近一月 | -1.91% | 1373/5421 |
| 近一季 | -3.71% | 1667/5231 |
| 近半年 | -0.86% | 1607/4920 |
| 近一年 | 4.84% | 1792/4394 |
| 近两年 | 42.88% | 1782/2954 |
| 近三年 | 30.57% | 1072/2253 |
| 成立以来 | 89.81% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.02% 3000/4961 |
8.96% 2514/5312 |
- - |
- - |
| 2025 | 16.64% 2430/4813 |
0.20% 1951/3635 |
2.12% 1846/4076 |
11.69% 3138/4524 |
2.06% 1092/4813 |
| 2024 | 16.90% 747/3463 |
2.01% 832/2808 |
0.60% 570/3014 |
14.95% 1866/3129 |
-0.90% 1540/3463 |
| 2023 | -4.16% 669/2656 |
4.78% 872/2280 |
-2.95% 723/2385 |
-1.15% 487/2515 |
-4.65% 1128/2655 |
| 2022 | -16.65% 501/2207 |
-11.55% 528/1919 |
7.47% 467/2016 |
-13.23% 861/2113 |
1.06% 1399/2208 |
| 2021 | -1.93% 827/1822 |
-0.45% 367/1255 |
4.64% 862/1330 |
-6.84% 999/1466 |
1.06% 1013/1822 |
| 2020 | 50.10% 170/1250 |
-4.21% 344/1028 |
16.77% 414/1067 |
18.58% 81/1164 |
13.17% 383/1184 |
| 2019 | 38.74% 299/1092 |
22.30% 852/1146 |
1.16% 229/1228 |
4.54% 195/850 |
7.27% 458/918 |
| 2018 | - - |
- - |
-3.74% 158/990 |
-2.61% 338/1000 |
-10.56% 337/1080 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富沪深300指数增强A VS. 长安沪深300非周期A(740101) |